Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic transplantation for haemoglobinopathies.

G Vassiliou1, P Amrolia, I A Roberts

  • 1Department of Haematology, Imperial College Faculty of Medicine, Hammersmith Hospital, London, UK.

Best Practice & Research. Clinical Haematology
|April 2, 2002
PubMed
Summary

Allogeneic stem cell transplantation (SCT) offers a cure for beta-thalassaemia major and sickle-cell disease (SCD). SCT is recommended for young thalassaemia patients and selected severe SCD cases, with varying survival benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience.

Bone marrow transplantation·2015
Same author

KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

Leukemia·2014
Same author

Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.

Leukemia·2014
Same author

Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients.

Bone marrow transplantation·2012
Same author

Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD.

Bone marrow transplantation·2011
Same author

Correlation of fl/d3 polymorphism of growth hormone receptor with the first- and second-year response to recombinant human growth hormone therapy in pre-pubertal Greek children with idiopathic isolated growth hormone deficiency.

Journal of endocrinological investigation·2010

Area of Science:

  • Hematology
  • Pediatric Hematology
  • Transplantation Medicine

Background:

  • Beta-thalassaemia major and sickle-cell disease (SCD) significantly impact lifespan and quality of life globally.
  • Allogeneic stem cell transplantation (SCT) is the only curative option for both beta-thalassaemia major and SCD.
  • Current treatment paradigms and decision-making for SCT differ significantly between these two genetic blood disorders.

Purpose of the Study:

  • To review the evidence guiding the recommendation of SCT for patients with beta-thalassaemia major and SCD.
  • To delineate the distinct criteria and outcomes associated with SCT for each condition.
  • To aid physicians in evaluating SCT for individual patient management.

Main Methods:

  • Review of existing evidence and clinical data on SCT outcomes for beta-thalassaemia major and SCD.

Related Experiment Videos

  • Comparative analysis of SCT decision-making processes for both diseases.
  • Evaluation of survival and disease-free survival rates post-SCT.

    • Main Results:

    • For beta-thalassaemia major, SCT is recommended for patients under 17, offering ~80% long-term survival and ~70% thalassaemia-free survival.
    • SCT provides a survival advantage for non-compliant thalassaemic patients but has inferior short-term survival compared to optimal medical care.
    • For severe SCD, particularly with neurological complications, SCT offers ~92% long-term survival and ~86% SCD-free survival.

    Conclusions:

    • SCT is a crucial curative therapy for beta-thalassaemia major and selected severe SCD cases.
    • Tailored approaches to SCT recommendation are essential due to the distinct pathophysiology and clinical heterogeneity of these disorders.
    • Physicians require comprehensive evidence to optimize SCT decision-making for individual patients.